Indevus Pharmaceuticals "hold," estimates reduced

08/10/06 - When2Trade Group

NEW YORK, August 10 (newratings.com) - Analysts at When2Trade Group reiterate their "hold" rating on Indevus Pharmaceuticals Inc (IDEV), while reducing their estimates for the company.

In a research note published yesterday, the analysts mention that the estimates for the future sales of SANCTURA and SANCTURA XR have been revised in view of the slow progress in quarterly sales of SANCTURA. The total sales estimate for 2006 has been reduced from $26 million to $22 million. The total SANCTURA and SANCTURA XR revenue estimates for 2007, 2008 and 2009 have been reduced from $38 million to $29 million, from $76 million to $57 million and from $114 million to $85 million, respectively. The EPS estimates for 2006, 2007, 2008 and 2009 have been reduced from -$0.76 to -$0.94, from -$0.75 to -$0.90, from -$0.35 to -$0.66 and from -$0.05 to -$0.47, respectively.